natgillin/translations-raw huggingface dataset:
: bør du fortælle det til din læge, hvis du skal have foretaget en planlagt operation (også hos skal du også fortælle det til din læge med det samme, hvis du udvikler en medicinsk tilstand (trombocytisk trombocytopenisk purpura eller TTP), der giver feber og blå mærker under huden, der kan fremstå som små røde prikker, med eller uden uforklarlig ekstrem træthed, forvirring, gulning af huden eller øjnene (gulsot) (se afsnit 4 'BIVIRKNINGER').
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects')
Ligesom andre antitrombotiske midler skal clopidogrel anvendes med forsigtighed til patienter med risiko for tiltagende blødninger pga. traumer, kirurgi eller andre patologiske tilstande samt til patienter, der samtidigt behandles med ASA, heparin, glykoprotein IIb/IIIa-hæmmere eller nonsteroide antiinflammatoriske lægemidler inklusive cox-2 hæmmere.
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors.
• Patienter med myokardieinfarkt (fra få dage, men ikke over 35 dage), iskæmisk slagtilfælde (fra 7 dage, men ikke over 6 måneder) eller påviste perifere kredsløbsforstyrrelser.
• Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
Hvis du bliver gravid, mens du tager Clopidogrel Teva Generics B.V., skal du omgående kontakte din læge, da det frarådes at tage Clopidogrel Teva Generics B.V., hvis du er gravid.
If you become pregnant while taking Clopidogrel Teva Generics B.V., consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
For yderligere oplysninger henvises til pkt.
For further information please refer to section 5.1.
Trombotisk trombocytopenisk purpura (TTP) (se afsnit 4.4), aplastisk anæmi, pancytopeni, agranulocytose, alvorlig trombocytopeni, granulocytopeni, anæmi
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia
Acetylsalicylsyre (ASA): ASA ændrede ikke på, at clopidogrel hæmmer den trombocytaggregation, som ADP inducerer, men clopidogrel forstærkede virkningen af ASA på den trombocytaggregation, som kollagen inducerer.
Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation.
Navn og adresse på fremstillerne ansvarlige for batchfrigivelse
Name and address of the manufacturer(s) responsible for batch release
28 filmovertrukne tabletter 28x1 filmovertrukne tabletter 30 filmovertrukne tabletter 30x1 filmovertrukne tabletter 50 filmovertrukne tabletter 50x1 filmovertrukne tabletter 56 filmovertrukne tabletter 56x1 filmovertrukne tabletter 84 filmovertrukne tabletter 84x1 filmovertrukne tabletter 90 filmovertrukne tabletter 90x1 filmovertrukne tabletter 100 filmovertrukne tabletter 100x1 filmovertrukne tabletter
28 film-coated tablets 28x1 film-coated tablets 30 film-coated tablets 30x1 film-coated tablets 50 film-coated tablets 50x1 film-coated tablets 56 film-coated tablets 56x1 film-coated tablets 84 film-coated tablets 84x1 film-coated tablets 90 film-coated tablets 90x1 film-coated tablets 100 film-coated tablets 100x1 film-coated tablets
Den gennemsnitlige hæmning af trombocytaggregation (IPA) med 5 µM ADP blev reduceret med 39 % (24 timer) og 21 % (dag 5), når clopidogrel og omeprazol blev administreret sammen.
Mean inhibition of platelet aggregation (IPA) with 5 μM ADP was diminished by 39% (24 hours) and 21% (Day 5) when clopidogrel and omeprazole were administered together.
• Patienter med akut koronarsyndrom
In patients suffering from acute coronary syndrome:
Femten procent (15,0 %) af patienterne i clopidogrel-gruppen og 21,7 % i placebogruppen opnåede det primære endpoint, hvilket viste en absolut reduktion på 6,7 % og en odds reduktion på 36 % til fordel for clopidogrel (95 % CI: 24, 47 %; p < 0.001), der hovedsagligt var relateret til en reduktion af infarkt-relaterede okkluderede arterier.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p<0.001), mainly related to a reduction in occluded infarct-related arteries.
Glykoprotein IIb/IIIa-hæmmere: Clopidogrel skal anvendes med forsigtighed til patienter, der samtidigt behandles med glykoprotein IIb/IIIa-hæmmere (se pkt.
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Farmakogenetik
Pharmacogenetics
Hjælpestoffer Dette lægemiddel indeholder hydrogeneret ricinusolie, der kan give maveproblemer og diarré.
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Overtræk:
Excipient:
Nonsteroide antiinflammatoriske stoffer (NSAID'er): I et klinisk forsøg foretaget på raske forsøgspersoner øgede den samtidige administration af clopidogrel og naproxen okkult gastrointestinalt blodtab.
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
I et klinisk crossover-forsøg blev clopidogrel (300 mg initialdosis efterfulgt af 75 mg/dag) administreret alene og sammen med omeprazol (80 mg på samme tidspunkt som clopidogrel) i 5 dage.
In a crossover clinical study, clopidogrel (300-mg loading dose followed by 75 mg/day) alone and with omeprazole (80 mg at the same time as clopidogrel) were administered for 5 days.
Ikke almindelige bivirkninger (hos 1 til 10 patienter ud af 1.000 patienter): Hovedpine, mavesår, opkastninger, kvalme, forstoppelse, luft i maven eller tarmene, udslæt, kløe, svimmelhed, prikkende fornemmelse og følelsesløshed.
Uncommon side effects (affects 1 to 10 patients in 1,000): Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness.
Patienterne fik clopidogrel (75mg/dag, n=22961) eller placebo (n=22891), i kombination med ASA (162 mg/dag) i 28 dage eller indtil udskrivelse fra hospitalet.
Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge.
I en delgruppeanalyse af inklusionsgrupperne (myokardieinfarkt, iskæmisk slagtilfælde og PAD) syntes udbyttet at være størst (dvs. den opnåede statiske signifikans ved p=0,003) hos patienter, som indgik på grund af PAD (især de patienter som tidligere også havde haft et myokardieinfarkt) (RRR = 23, 7%, CI: 8,9 til 36,2) og mindst (afveg ikke signifikant fra ASA) hos patienter med slagtilfælde (RRR = 7,3 %, CI: -5,7 til 18,7 [p=0,258]).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]).
Blødning i luftvejene (hæmoptyse, pulmonær blødning), bronkospasmer, interstitiel pneumoni
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis
Forekomsten af større blødninger var ensartet i de to grupper (1.3 % versus 1.1 % for hhv. clopidogrel+ASA- og placebo+ASA-gruppen.)
The incidence of major bleeding was similar between groups (1.3% versus 1.1% for the clopidogrel + ASA and the placebo + ASA groups, respectively).
- Akut myokardieinfarkt med elevation af ST-segmentet: Behandling med clopidogrel bør bestå af en daglig dosering på 75 mg, indledt med en initialdosis på 300 mg i kombination med ASA og med eller uden trombolytika.
− ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics.
til forebyggelse af blodpropper og nedsættelse af risikoen for disse alvorlige hændelser, fordi: - Du lider af åreforkalkning (også kaldet aterosklerose) - og - Du tidligere har haft et hjerteanfald, slagtilfælde eller kredsløbsforstyrrelser i arme eller ben - eller - Du har haft en alvorlig form for smerter i brystet, som kaldes hjertekrampe (ustabil angina pectoris) eller hjerteanfald (myokardieinfarkt).
You have been prescribed Clopidogrel Teva Generics B.V. to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack).
til sædvanlig tid, men kommer i tanke om det i løbet af 12 timer, skal du omgående tage tabletten og dernæst tage den næste tablet til sædvanlig tid.
If you forget to take a dose of Clopidogrel Teva Generics B.V., but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
Spørg på apoteket hvordan du skal aflevere medicinrester.
Ask your pharmacist how to dispose of medicines no longer required.
Hvis du mener, at ovenstående gælder for dig, eller hvis du overhovedet er i tvivl, så rådfør dig med din læge, inden du tager Clopidogrel Teva Generics B.V.
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Teva Generics B.V..
Mavesår og duodenalt ulcus gastritis, opkastning, kvalme, forstoppelse, flatulens
Gastric ulcer and duodenal ulcer, gastritis, vomiting, nausea, constipation, flatulence
tages for at forebygge dannelse af blodpropper (trombi) i blodårer (arterier), som er blevet stive ved en proces kaldet aterotrombose, hvilket kan føre til aterotrombotiske hændelser (f.eks. slagtilfælde, hjerteanfald og død).
Clopidogrel Teva Generics B.V. is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
I intention-to-treat-analysen blev der observeret 939 tilfælde i clopidogrelgruppen og 1.020 tilfælde i ASA-gruppen (relativ risikoreduktion (RRR) 8,7 % [95 % CI: 0,2-16,4], p=0,045), hvilket for hver 1.000 patienter, der blev behandlet i 2 år, svarer til, at yderligere 10 [CI: 0-20] patienter beskyttes mod et nyt iskæmisk tilfælde.
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p = 0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Alvorlig blødning, blødning i operationssår, vaskulitis, hypotension
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension
• du lider af en nyre- eller leversygdom.
• if you have kidney or liver disease.
- akut koronarsyndrom uden elevation af ST-segmentet (ustabil angina eller myokardieinfarkt uden forekomst af Q-takker) inklusive patienter, som får indsat stent efter perkutant koronarindgreb, i kombination med acetylsalicylsyre (ASA).
• Patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
Syrepumpehæmmere (PPI):
Proton Pump Inhibitors (PPI):
Som forholdsregel frarådes samtidig anvendelse af omeprazol eller esomeprazol (se pkt.
As a precaution, concomitant use of omeprazole or esomeprozole should be discouraged (see section 4.4).
Patienterne blev randomiseret til clopidogrel (300 mg initialdosis efterfulgt af 75 mg/dag, N=6.259) eller placebo (N=6.303), begge i kombination med ASA (75-325 mg en gang daglig) samt anden standardbehandling.
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies.
Fremstillere:
Manufacturer
Brug af anden medicin:
Taking other medicines
Antallet af patienter, som oplevede det primære endpoint [kardiovaskulært dødsfald, myokardieinfarkt eller slagtilfælde] var 582 (9,3 %) i clopidogrel-gruppen og 719 (11,4 %) i placebogruppen, hvilket giver en relativ risikoreduktion på 20 % (95 % CI: 10 %-28 %; p=0,00009) for clopidogrelgruppen (en relativ risikoreduktion på 17 %, når patienterne fik konservativ behandling, 29 %, når de fik perkutan transluminal koronar angioplasti (PTCA) med eller uden stent og 10 %, når de fik koronar bypassoperation (CABG)).
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
Risikoen for blødninger (livstruende, større, mindre, andre) faldt under forsøgsforløbet: 0-1 måned (clopidogrel: 9,6 %; placebo: 6,6 %), 1-3 måneder (clopidogrel: 4,5 %; placebo 2,3 %), 3-6 måneder (clopidogrel 3,8 %; placebo: 1,6 %), 6-9 måneder (clopidogrel: 3,2 %; placebo 1,5 %), 9-12 måneder (clopidogrel 1,9 %; placebo 1,0 %).
In CURE, the major bleeding event rate for clopidogrel + ASA was dose-dependent on ASA (<100 mg: 2.6%; 100-200 mg: 3.5%; >200 mg: 4.9%) as was the major bleeding event rate for placebo + ASA (<100 mg: 2.0%; 100-200 mg: 2.3%; >200 mg: 4.0%).The risk of bleeding (life-threatening, major, minor, other) decreased during the course of the trial: 0-1 months (clopidogrel: 9.6%; placebo: 6.6%), 1-3 months (clopidogrel: 4.5%; placebo: 2.3%), 3-6 months (clopidogrel: 3.8%; placebo: 1.6%), 6-9 months (clopidogrel: 3.2%; placebo: 1.5%), 9-12 months (clopidogrel: 1.9%; placebo: 1.0%).
Muskuloskeletal blødning (blødudtrædning i led), artrit, arthralgi, muskelsmerter.
Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia
Lavere eksponering for den aktive metabolit resulterer i mindre trombocythæmning eller mulighed for trombocytaggregation i de resterende ikke-hæmmede trombocytter.
Lower active metabolite exposure results in less platelet inhibition or higher residual platelet reactivity.
Hvis du har haft alvorlige brystsmerter (hjertekrampe (ustabil angina pectoris) eller hjertetilfælde), vil din læge måske indlede behandlingen med at give dig 300 mg Clopidogrel Teva Generics B.V.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Teva Generics B.V. (4 tablets of 75 mg) once at the start of treatment.
Farmakokinetikken og den antitrombotiske effekt, målt ved ex vivo trombocytaggregationsundersøgelse, adskiller sig alt efter CYP2C19 genotype.
Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.
Antallet af patienter, som oplevede det primære endpoint [kardiovaskulært dødsfald, myokardieinfarkt, slagtilfælde eller refraktær iskæmi] var 1.035 (16,5 %) i clopidogrelgruppen og 1.187 (18,8 %) i placebogruppen, hvilket giver en relativ risikoreduktion på 14 % (95 % CI: 6 %-21 %; p=0,00005) for clopidogrelgruppen.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebotreated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogreltreated group.
NAVN PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN Teva Generics B.V.
NAME OF THE MARKETING AUTHORISATION HOLDER Teva Generics B.V.
• Stærkt nedsat leverfunktion.
• Severe liver impairment.
Hos patienter med akut koronarsyndrom: - Akut koronarsyndrom uden elevation af ST-segmentet (ustabil angina pectoris eller myokardieinfarkt uden forekomst af Q-takker): Behandling med clopidogrel bør indledes med en enkelt initialdosis på 300 mg, hvorefter behandlingen består af 75 mg en gang daglig (sammen med acetylsalicylsyre (ASA) 75 mg - 325 mg/dag).
− Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
MINDSTEKRAV TIL OPLYSNINGER PÅ BLISTERKORT ELLER BLISTERSTRIPS BLISTERPAKNING (28, 28x1, 30, 30x1, 50, 50x1, 56, 56x1, 84, 84x1, 90, 90x1, 100, 100x1 filmovertrukne tabletter)
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (28, 28x1, 30, 30x1, 50, 50x1, 56, 56x1, 84, 84x1, 90, 90x1, 100, 100x1 film-coated tablets)
KVALITATIV OG KVANTITATIV SAMMENSÆTNING En filmovertrukken tablet indeholder 75 mg clopidogrel (som hydrochlorid) Hjælpestoffer:
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrochloride).
Samtidig indgift af heparin havde ingen virkning på den hæmning af trombocytaggregationen, som clopidogrel inducerer.
Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel.
Efter gentagen dosering med clopidogrel 75 mg daglig i 10 dage svarede den ADP-inducerede trombocytaggregation hos patienter med alvorligt nedsat leverfunktion til den, der blev set hos raske forsøgspersoner.
After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.
Moderat metabolisme: CYP2C19*1/*2 eller *1/*3 Ringe metabolisme: CYP2C19*2/*2, *2/*3 eller
Poor metabolism: CYP2C19*2/*2, *2/*3 or *3/*3
UDLØBSDATO Udløbsdato {MM/ÅÅÅÅ}
EXPIRY DATE
Som forholdsregel bør amning ophøre under behandling med Clopidogrel Teva Generics B.V..
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Teva Generics B.V..
I tabellen nedenfor ses frekvenserne for de almindelige CYP2C19fænotyper og -genotyper.
Published frequencies for the common CYP2C19 phenotypes and genotypes are listed in the table below.
: Hvis nogen af følgende situationer gælder for dig, skal du oplyse det til din læge, før du tager Clopidogrel Teva Generics B.V.
If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Teva Generics B.V.:
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 75 mg clopidogrel (som hydrochlorid).
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 75 mg of clopidogrel (as hydrochloride).
y Farmakogenetik
• Pharmacogenetics
: Almindelige bivirkninger (hos 1 til 10 patienter ud af 100 patienter): Diaré, mavesmerter fordøjelsesbesvær eller halsbrand,
Common side effects (affects 1 to 10 patients in 100): Diarrhoea, abdominal pain, indigestion or heartburn.
Patienterne fik clopidogrel (300 mg initialdosis efterfulgt af 75 mg daglig, n=1.752) eller placebo (n=1.739) begge i kombination med ASA (150-325 mg som initialdosis, herefter 75-162 mg dagligt), et fibrinolytisk middel samt heparin, når det var hensigtsmæssigt.
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Mave-tarmkanalen Gastrointestinal blødning, diarré, mavesmerter, dyspepsi
Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia
Tlf: +45 44 98 55 11
Danmark Teva Denmark A.S. Tlf: +45 44 98 55 11
Visse andre typer medicin kan påvirke brugen af Clopidogrel Teva Generics B.V.
Some other medicines may influence the use of Clopidogrel Teva Generics B.V. or vice versa.
Blødning og hæmatologiske sygdomme
Bleeding and haematological disorders
INDEHAVERE AF VIRKSOMHEDSGODKENDELSER ANSVARLIGE FOR BATCHFRIGIVELSE
A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Efter gentagen dosering med clopidogrel 75 mg daglig var hæmningen af ADP-induceret trombocytaggregation lavere (25 %) hos forsøgspersoner med alvorlig nyresygdom (kreatininclearance 5-15 ml/min) end der, der blev set hos raske forsøgspersoner.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min) inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Hydrogeneret ricinusolie
Hydrogenated castor oil
Hvis du får langvarige blødninger, mens du tager Clopidogrel Teva Generics B.V.
If you experience prolonged bleeding when taking Clopidogrel Teva Generics B.V.
75 mg filmovertrukne tabletter Clopidogrel
Clopidogrel Teva Generics B.V. 75 mg film-coated tablets Clopidogrel
INDEHAVER AF MARKEDSFØRINGSTILLADELSE
CONDITIONS OF THE MARKETING AUTHORISATION
Indenfor hver gruppe af bivirkninger med samme frekvens er bivirkningerne opstillet efter, hvor alvorlige bivirkningerne er.
Within each system organ class, adverse drug reactions are presented in order of decreasing seriousness.
Der er begrænset erfaring med behandling af patienter med nyresygdom.
Therapeutic experience with clopidogrel is limited in patients with renal impairment.
Æsker med 28, 30, 50, 56, 84, 90 eller 100 filmovertrukne tabletter i blisterpakning eller æsker med 28x1, 28x1 (kalenderpakning), 30x1, 50x1, 56x1, 84x1, 90x1 og 100x1 filmovertrukne tabletter i perforerede enhedsdosisblistere.
Boxes of 28, 30, 50, 56, 84, 90 or 100 film-coated tablets in blisters or boxes of 28x1, 28x1 (calendar pack), 30x1, 50x1, 56x1, 84x1, 90x1 and 100x1 film-coated tablets in perforated unit dose blisters are available.
: Kontakt din læge eller tag på den nærmeste skadestue på grund af den øgede blødningsrisiko.
If you take more Clopidogrel Teva Generics B.V. than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Blisterkort af OPA/Al/PVC-Al i æsker med 28, 30, 50, 56, 84, 90 og 100 filmovertrukne tabletter eller perforerede enhedsdosisblistere af OPA/Al/PVC-Al indeholdende 28x1, 28x1 (kalenderpakning), 30x1, 50x1, 56x1, 84x1, 90x1 og 100x1 filmovertrukne tabletter i kartonæsker.
OPA/Al/PVC-Al blisters containing 28, 30, 50, 56, 84, 90 and 100 film-coated tablets or perforated unit dose blister containing 28x1, 28x1 (calendar pack), 30x1, 50x1, 56x1, 84x1, 90x1 and 100x1 film-coated tablets in a carton.
Som forholdsregel frarådes samtidig anvendelse af lægemidler, der hæmmer CYP2C19 (se pkt.
As a precaution concomitant use of medicinal products that inhibit CYP2C19 should be discouraged (see sections 4.4 and 5.2).
Man Tirs Ons Tors Fre Lør Søn
Mon Tue Wed Thu Fri Sat Sun
Nyligt iskæmisk slagtilfælde
Recent ischaemic stroke